文献速递外周动脉疾病

血运重建联合监督运动治疗症状性外周动脉疾病的系统评价与Meta分析

Evaluating the Added Value of Combined Revascularization and Supervised Exercise Therapy in Symptomatic Peripheral Artery Disease: A Systematic Review and Meta-Analysis with a Focus on Functional and Patient-Reported Outcomes.
PubMed 文献 · Ann Vasc Surg · 2026-07-14

该系统评价与Meta分析纳入7项随机对照试验共712例Fontaine II-III期症状性外周动脉疾病患者,比较血运重建联合监督运动治疗与单独血运重建或单独监督运动治疗。结果显示联合治疗显著改善最大步行距离、无痛步行距离和SF-36心理健康评分,但踝肱指数、SF-36生理健康评分和12个月再干预率无显著差异。

要点

  • 联合治疗较单药治疗显著提高最大步行距离(MD 106.35 m)。
  • 联合治疗显著改善无痛步行距离和SF-36心理健康评分。
  • 踝肱指数、生理健康评分和再干预率无显著差异。

核心结论

  • 在症状性外周动脉疾病患者中,血运重建联合监督运动治疗较单药治疗可能额外改善步行能力和心理健康。

研究设计与样本

  • 系统评价与Meta分析,检索Medline、Embase、Cochrane Central和Web of Science至2024年10月4日,纳入7项随机对照试验共712例Fontaine II-III期患者。

主要发现

  • 联合治疗显著改善最大步行距离(MD 106.35 m;95%CI 46.54-166.17)。
  • 联合治疗显著改善无痛步行距离(MD 166.24 m;95%CI 16.29-316.18)。
  • 联合治疗显著改善SF-36心理健康评分(MD 4.11;95%CI 3.45-4.77)。
  • 踝肱指数无显著差异(MD 0.10;95%CI 0.00-0.19)。
  • SF-36生理健康评分无显著差异(MD 5.13;95%CI -6.88至17.14)。

临床怎么用

  • 对Fontaine II-III期症状性外周动脉疾病患者,可考虑血运重建联合监督运动治疗以改善步行能力和心理健康。

局限性

  • 运动干预和结局定义存在异质性。
  • 纳入研究存在高偏倚风险,证据确定性受限。
  • 需要进一步高质量随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral artery disease (PAD) affects over 236 million individuals globally and remains a major cause of functional limitation, disability, and limb loss. In symptomatic PAD, reduced lower limb perfusion leads to intermittent claudication and diminished quality of life. This systematic review and meta-analysis aimed to determine whether combining revascularization with supervised exercise therapy (SET) yields superior clinical outcomes compared to either treatment alone in patients with Fontaine stage II-III PAD. METHODS: A comprehensive search of Medline, Embase, Cochrane Central, and Web of Science was performed on October 4, 2024. Randomized controlled trials comparing combined revascularization and SET versus revascularization or SET alone were included. Primary outcome was the maximum walking distance (MWD). Secondary outcomes were pain-free walking distance (PFWD), ankle-brachial index (ABI), health-related quality of life assessed by Short Form Health Survey (SF-36) physical and mental health scores, and vascular reintervention at 12 months. Meta-analyses used random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework. RESULTS: Seven trials met the inclusion criteria, enrolling 712 patients. Combined therapy significantly improved MWD (mean difference [MD] 106.35 m; 95% confidence interval [CI], 46.54-166.17), PFWD (MD 166.24 m; 95% CI, 16.29-316.18), and SF-36 mental health score (MD 4.11; 95% CI, 3.45-4.77). No significant differences were observed for ABI (MD 0.10; 95% CI, 0.00-0.19), SF-36 physical health score (MD 5.13; 95% CI, -6.88 to 17.14), or subsequent intervention rates (odds ratio 0.32; 95% CI, 0.08-1.39). Heterogeneity in exercise intervention and outcome definitions represented limitations. CONCLUSION: In symptomatic PAD, the combination of revascularization with SET may yield additional improvements in walking performance and mental health compared to monotherapy. However, these findings are tempered by methodological limitations, including high risk of bias and heterogeneity, underscoring the need for further high-quality randomized trials.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Marchand C, Savoie-White FH, Patry J, et al. Evaluating the Added Value of Combined Revascularization and Supervised Exercise Therapy in Symptomatic Peripheral Artery Disease: A Systematic Review and Meta-Analysis with a Focus on Functional and Patient-Reported Outcomes. Ann Vasc Surg. 2026. PMID: 42448037. doi:10.1016/j.avsg.2026.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。